Sodium Chloride 0.9% Injecti · 282 days since initial FDA posting
Brand: SODIUM CHLORIDE
FDA lists Sodium Chloride 0.9% Injecti as To Be Discontinued (Hospira, Inc., a Pfizer Company).
No availability text on this FDA row.
Sodium Chloride 0.9% Injection: To Be Discontinued
FDA availability text is not recorded on this row. Contact your pharmacist if you are affected.
Shortage Details
- Generic Name
- Sodium Chloride 0.9% Injection
- Manufacturer
- Hospira, Inc., a Pfizer Company
- Dosage Form
- Injection
- Presentation
- Sodium Chloride 0.9%, Injection, 50 mL ADD-Vantage® Flexible Container (NDC 0409-7101-66)
- Package NDC
- 0409-7101-66
Status & Timeline
- Status
- To Be Discontinued
- First Reported
- Dec 3, 2025
- Last Updated
- Dec 3, 2025
- Therapeutic Category
- Gastroenterology, Other, Renal
Row fields from the FDA Drug Shortages database via openFDA.
Shortage Reason
Discontinuation of the manufacture of the drug
Nearby, Other Sodium Shortage Records
Sodium Chloride 0.9% Injection
Hospira, Inc., a Pfizer Company
Injection
Sodium Chloride 0.9% Injection
Hospira, Inc., a Pfizer Company
Injection
Sodium Chloride 0.9% Injection
Fresenius Medical Care North America
Injection
Sodium Chloride 0.9% Injection
Fresenius Medical Care North America
Injection
FDA reason on file: Discontinuation of the manufacture of the drug. General shortage guidance lives on the tracker hub.